Cargando…

Occult hepatitis C virus infection in patients with malignant lymphoproliferative disorders

Despite the link between HCV and malignant lymphoproliferative disorders has been established, the association between occult hepatitis C virus infection and malignant lymphoproliferative disorders remains obscure. The present study intended to identify the possible association between occult HCV in...

Descripción completa

Detalles Bibliográficos
Autores principales: Lotfi, Abeya A, Mohamed, Asmaa E, Shalaby, Nahela A, Eissa, Deena S, El-Dabaa, Ehab, Sallam, Ayman M, Kamel, Mahmoud M, Abdelaziz, Hisham, El-Afifi, Amal M, Abdel-Moneim, Ahmed S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7557643/
https://www.ncbi.nlm.nih.gov/pubmed/33045856
http://dx.doi.org/10.1177/2058738420961202
_version_ 1783594466630696960
author Lotfi, Abeya A
Mohamed, Asmaa E
Shalaby, Nahela A
Eissa, Deena S
El-Dabaa, Ehab
Sallam, Ayman M
Kamel, Mahmoud M
Abdelaziz, Hisham
El-Afifi, Amal M
Abdel-Moneim, Ahmed S
author_facet Lotfi, Abeya A
Mohamed, Asmaa E
Shalaby, Nahela A
Eissa, Deena S
El-Dabaa, Ehab
Sallam, Ayman M
Kamel, Mahmoud M
Abdelaziz, Hisham
El-Afifi, Amal M
Abdel-Moneim, Ahmed S
author_sort Lotfi, Abeya A
collection PubMed
description Despite the link between HCV and malignant lymphoproliferative disorders has been established, the association between occult hepatitis C virus infection and malignant lymphoproliferative disorders remains obscure. The present study intended to identify the possible association between occult HCV infection and malignant lymphoproliferative disorders. Newly diagnosed patients with LPDs were screened for the presence of HCV-RNA in both plasma and PBMCs. PBMCs of the subjects were also, examined by transmission and immuno-electron microscopy. LPD patients showed a high percentage of HCV infection (71.9%): OCI-HCV (37.5%) and HCV (34.38%). Meanwhile, 28.13% of LPD patients did not show any evidence of HCV infection. Ultrastructural examination of PBMCs revealed the presence of intracytoplasmic vacuoles enclosing viral like particles, which were less prominent in occult HCV patients. The possibility of occult HCV should be considered in patients with LPDs which can be helpful in the management of the treatment protocol in order to set up a balance between the control of the tumor progression and minimizing post chemotherapy complications related to HCV infection.
format Online
Article
Text
id pubmed-7557643
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-75576432020-10-26 Occult hepatitis C virus infection in patients with malignant lymphoproliferative disorders Lotfi, Abeya A Mohamed, Asmaa E Shalaby, Nahela A Eissa, Deena S El-Dabaa, Ehab Sallam, Ayman M Kamel, Mahmoud M Abdelaziz, Hisham El-Afifi, Amal M Abdel-Moneim, Ahmed S Int J Immunopathol Pharmacol Original Research Article Despite the link between HCV and malignant lymphoproliferative disorders has been established, the association between occult hepatitis C virus infection and malignant lymphoproliferative disorders remains obscure. The present study intended to identify the possible association between occult HCV infection and malignant lymphoproliferative disorders. Newly diagnosed patients with LPDs were screened for the presence of HCV-RNA in both plasma and PBMCs. PBMCs of the subjects were also, examined by transmission and immuno-electron microscopy. LPD patients showed a high percentage of HCV infection (71.9%): OCI-HCV (37.5%) and HCV (34.38%). Meanwhile, 28.13% of LPD patients did not show any evidence of HCV infection. Ultrastructural examination of PBMCs revealed the presence of intracytoplasmic vacuoles enclosing viral like particles, which were less prominent in occult HCV patients. The possibility of occult HCV should be considered in patients with LPDs which can be helpful in the management of the treatment protocol in order to set up a balance between the control of the tumor progression and minimizing post chemotherapy complications related to HCV infection. SAGE Publications 2020-10-13 /pmc/articles/PMC7557643/ /pubmed/33045856 http://dx.doi.org/10.1177/2058738420961202 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Research Article
Lotfi, Abeya A
Mohamed, Asmaa E
Shalaby, Nahela A
Eissa, Deena S
El-Dabaa, Ehab
Sallam, Ayman M
Kamel, Mahmoud M
Abdelaziz, Hisham
El-Afifi, Amal M
Abdel-Moneim, Ahmed S
Occult hepatitis C virus infection in patients with malignant lymphoproliferative disorders
title Occult hepatitis C virus infection in patients with malignant lymphoproliferative disorders
title_full Occult hepatitis C virus infection in patients with malignant lymphoproliferative disorders
title_fullStr Occult hepatitis C virus infection in patients with malignant lymphoproliferative disorders
title_full_unstemmed Occult hepatitis C virus infection in patients with malignant lymphoproliferative disorders
title_short Occult hepatitis C virus infection in patients with malignant lymphoproliferative disorders
title_sort occult hepatitis c virus infection in patients with malignant lymphoproliferative disorders
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7557643/
https://www.ncbi.nlm.nih.gov/pubmed/33045856
http://dx.doi.org/10.1177/2058738420961202
work_keys_str_mv AT lotfiabeyaa occulthepatitiscvirusinfectioninpatientswithmalignantlymphoproliferativedisorders
AT mohamedasmaae occulthepatitiscvirusinfectioninpatientswithmalignantlymphoproliferativedisorders
AT shalabynahelaa occulthepatitiscvirusinfectioninpatientswithmalignantlymphoproliferativedisorders
AT eissadeenas occulthepatitiscvirusinfectioninpatientswithmalignantlymphoproliferativedisorders
AT eldabaaehab occulthepatitiscvirusinfectioninpatientswithmalignantlymphoproliferativedisorders
AT sallamaymanm occulthepatitiscvirusinfectioninpatientswithmalignantlymphoproliferativedisorders
AT kamelmahmoudm occulthepatitiscvirusinfectioninpatientswithmalignantlymphoproliferativedisorders
AT abdelazizhisham occulthepatitiscvirusinfectioninpatientswithmalignantlymphoproliferativedisorders
AT elafifiamalm occulthepatitiscvirusinfectioninpatientswithmalignantlymphoproliferativedisorders
AT abdelmoneimahmeds occulthepatitiscvirusinfectioninpatientswithmalignantlymphoproliferativedisorders